Abstract:BackgroundPatients with Alzheimer’s Disease (AD) exhibit structural alterations of the thalamus that correlate with clinical symptoms. However, given the anatomical complexity of this brain structure, it is still unclear whether atrophy affects specific thalamic nuclei and modulates the clinical progression from a prodromal stage, known as Mild Cognitive Impairment (MCI), to full-fledged AD.ObjectivesTo characterize the structural integrity of distinct thalamic nuclei across the AD spectrum, testing whether MCI patients who convert to AD (c-MCI) show a distinctive pattern of thalamic structural alterations compared to patients who remain stable (s-MCI).DesignInvestigating between-group differences in the volumetric features of distinct thalamic nuclei across the AD spectrum.SettingProdromal and clinical stages of AD.ParticipantsWe analyzed data from 84 healthy control subjects (HC), 58 individuals with MCI, and 102 AD patients. The dataset was obtained from the AD Neuroimaging Initiative (ADNI-3) database. The MCI group was further divided into two subgroups depending on whether patients remained stable (s-MCI, n=22) or progressed to AD (s-MCI, n=36) in the 48 months following the diagnosis.MeasurementsA multivariate analysis of variance (MANOVA) assessed group differences in the volumetric features of distinct thalamic nuclei obtained from magnetic resonance (MR) images. A stepwise discriminant function analysis identified which feature most effectively predicted the conversion to AD. The corresponding predictive performance was evaluated through a Receiver Operating Characteristic approach.ResultsAD and c-MCI patients showed generalized atrophy of thalamic nuclei compared to HC. In contrast, no significant structural differences were observed between s-MCI and HC subjects. Compared to s-MCI, c-MCI individuals displayed significant atrophy of the nucleus reuniens and a trend toward significant atrophy in the anteroventral and laterodorsal nuclei. The discriminant function analysis confirmed the nucleus reuniens as a significant predictor of AD conversion, with a sensitivity of 0.73 and a specificity of 0.69.ConclusionsIn line with the pathophysiological relevance of the nucleus reuniens proposed by seminal post-mortem studies on patients with AD, we confirm the pivotal role of this nucleus as a critical hub in the clinical progression to AD. We also propose a theoretical model to explain the evolving dysfunction of subcortical brain networks in the disease process.

Nucleus Basalis of Meynert degeneration predicts cognitive decline in Corticobasal Syndrome

Cerebellar Atrophy and Its Contribution to Cognition in Frontotemporal Dementias.

Degeneration in Nucleus basalis of Meynert signals earliest stage of Alzheimer's disease progression

Meynert Nucleus-Related Cortical Thinning in Parkinson's Disease with Mild Cognitive Impairment.

Loss of synaptic density in nucleus basalis of meynert indicates distinct neurodegeneration in Alzheimer's disease: the RJNB-D study

Degeneration of cholinergic white matter pathways and nucleus basalis of Meynert in individuals with objective subtle cognitive impairment

Loss of Synaptic Density in Nucleus Basalis of Meynert Indicates Distinct Neurodegeneration in Alzheimer’s Disease: the RJNB-D Study

Altered Functional Connectivity Pattern of Hippocampal Subfields in Individuals with Objectively-Defined Subtle Cognitive Decline and Its Association with Cognition and Cerebrospinal Fluid Biomarkers

Increased Functional Connectivity Between Nucleus Basalis of Meynert and Amygdala in Cognitively Intact Elderly along the Alzheimer’s Continuum

Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study

Differential Synaptic Loss in β‐Amyloid Positive Versus β‐Amyloid Negative Corticobasal Syndrome

Prediction of clinical progression of subjective cognitive decline through alterations in morphology and structural covariance networks

Hippocampal subfield volumetry in corticobasal syndrome of diverse underlying pathologies

Lateral thinking: Neurodegeneration of the cortical cholinergic system in Alzheimer's disease

Association of Basal Forebrain Atrophy With Cognitive Decline in Early Alzheimer Disease

Lateral Thinking: Pathway Specific Neurodegeneration of the Cortical Cholinergic System in Alzheimer's Disease

Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy

Regional transcriptional vulnerability to basal forebrain functional dysconnectivity in mild cognitive impairment patients

“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer’s Disease Progression

Evaluating the Effect of Alzheimer's Disease‐Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy